KR100971305B1 - 신장 질환용 진단 표지로서의 호중구 젤라티나제 결합리포칼린 (ngal)의 측정 - Google Patents
신장 질환용 진단 표지로서의 호중구 젤라티나제 결합리포칼린 (ngal)의 측정 Download PDFInfo
- Publication number
- KR100971305B1 KR100971305B1 KR1020077016768A KR20077016768A KR100971305B1 KR 100971305 B1 KR100971305 B1 KR 100971305B1 KR 1020077016768 A KR1020077016768 A KR 1020077016768A KR 20077016768 A KR20077016768 A KR 20077016768A KR 100971305 B1 KR100971305 B1 KR 100971305B1
- Authority
- KR
- South Korea
- Prior art keywords
- ngal
- urine
- concentration
- sample
- disease
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Description
환자 번호 | 진단 |
u-NGAL
순위 ng/㎖ |
s-NGAL
순위 ng/㎖ |
p-크레아티닌
순위 μM |
호중구
순위 x 109/㎖ |
s-CRP
순위 ㎍/㎖ |
1 | MT, 요량 감소증 |
10 8640 |
10 435 |
10 366 |
11 15.6 |
2 31 |
2 | 대동맥류 파열, 무뇨증, 혈액 투석 | 7 1490 |
9 342 |
11 605 |
7 9.6 |
6 71 |
3 | B-cell ALL, 폐렴 |
9 3800 |
8 330 |
2 63 |
2 2.0 |
10 97 |
4 | 대변 복막염 |
8 2700 |
7 273 |
7 108 |
9 16 |
9 87 |
5 | 구균(S. aureus) 패혈증, ATN | 11 15,700 |
11 922 |
6 103 |
8 13.9 |
8 81 |
6 | AML, 패혈 쇼크 | 6 1030 |
5 146 |
9 164 |
1 <0.1 |
4 56 |
7 | HRS 장구균(E. faecalis) 균혈증 |
3 900 |
3 92 |
3 82 |
5 6.7 |
1 19 |
8 | 혈종, ARDS |
5 1000 |
4 114 |
8 154 |
6 9.5 |
3 37 |
9 | MT |
1 110 |
1 66 |
4 91 |
4 5.7 |
11 103 |
10 | MT |
4 950 |
6 147 |
5 98 |
3 5.0 |
7 81 |
11 | 비장 절제, 천공된 횡경막 | 2 130 |
2 79 |
1 30 |
10 19 |
5 62 |
혈장NGAL
ng/㎖ |
소변NGAL
ng/㎖ |
임상학적 분류 | ||||
환자 번호 | 신장 질환 | 패혈증 | 암 | 혈액 투석 | ||
1 | 92 | 50 | - | - | - | - |
2 | 1005 | 5000 | + | - | - | + |
3 | 151 | 183 | - | + | - | - |
6 | 1320 | 5000 | + | + | - | + |
7 | 777 | 3229 | + | + | + | + |
8 | 712 | 269 | + | + | + | - |
9 | 2941 | 5000 | + | - | - | + |
10 | 3092 | 5000 | + | - | - | + |
11 | 65 | 13 | - | - | - | - |
12 | 2117 | 5000 | + | + | - | + |
15 | 546 | 3128 | + | + | + | - |
17 | 110 | 10 | + | - | - | - |
18 | 135 | 68 | - | - | - | - |
19 | 191 | 2672 | + | + | + | + |
20 | 336 | 304 | - | - | + | - |
21 | 1434 | 5000 | + | + | - | + |
24 | 307 | 1042 | + | - | - | + |
29 | 71 | 50 | - | - | - | - |
30 | 320 | 874 | - | - | - | - |
39 | 1416 | 1073 | + | + | - | - |
41 | 181 | 42 | - | - | - | - |
42 | 115 | 29 | - | - | - | - |
43 | 436 | 176 | + | - | - | - |
44 | 446 | 680 | + | - | - | - |
45 | 270 | 37 | - | - | - | - |
46 | 1962 | 3222 | + | + | + | + |
47 | 222 | 89 | - | + | - | - |
48 | 1040 | 3974 | + | - | - | + |
49 | 228 | 48 | - | - | - | |
51 | 256 | 519 | + | - | + | + |
52 | 294 | 685 | + | + | + | - |
53 | 586 | 1337 | + | + | + | - |
54 | 1376 | 2915 | + | - | + | + |
55 | 1276 | 5000 | + | + | + | + |
57 | 180 | 24 | - | - | - | - |
58 | 716 | 3431 | + | - | - | + |
59 | 108 | 9 | - | + | - | - |
60 | 1219 | 2713 | + | + | + | + |
65 | 460 | 1705 | - | - | + | - |
67 | 1470 | 5000 | + | - | - | + |
69 | 318 | 68 | - | + | - | - |
72 | 175 | 17 | - | - | - | - |
75 | 645 | 3360 | + | - | + | + |
80 | 322 | 328 | - | + | + | - |
82 | 216 | 30 | - | + | - | - |
83 | 259 | 34 | - | + | - | - |
84 | 25 | 20 | - | - | - | - |
85 | 1067 | 370 | + | + | - | + |
86 | 64 | 21 | - | - | - | - |
87 | 276 | 779 | + | - | - | - |
88 | 302 | 1024 | - | + | - | - |
91 | 236 | 17 | - | - | - | - |
93 | 1595 | 5000 | + | + | - | + |
97 | 3491 | 708 | + | + | + | + |
99 | 820 | 401 | + | + | - | + |
100 | 354 | 85 | - | - | + | - |
101 | 1144 | 5000 | + | + | + | + |
104 | 1844 | 2748 | + | + | - | + |
105 | 488 | 4473 | + | - | - | + |
108 | 111 | 46 | - | + | - | - |
Claims (22)
- ⅰ) 인간의 체액 시료 중 인간 호중구 젤라티나제 결합 리포칼린 (NGAL)의 농도를 측정하는 단계와,ⅱ) 상기 상기 단계 i)에서 측정한 NGAL 농도와 미리 결정된 컷오프(cutoff) 값의 차이를 표시하는 단계를 포함하고,상기 컷오프 값은 250 ng/㎖ ~ 525 ng/㎖ 범위인인간의 신장 질환 가능성을 관찰 또는 결정하기 위한 정보를 제공하는 방법.
- 제1항에 있어서, 상기 시료는 소변 시료인 것인 방법.
- 제1항에 있어서, 상기 시료는 혈장 또는 혈청 시료인 것인 방법.
- 삭제
- 삭제
- 삭제
- 제1항에 있어서, 단계 ⅰ)과 ⅱ)를 반복하는 단계를 더 포함하는 것인 관찰 방법.
- 제1항에 있어서, 24 시간 내에 ⅰ) 및 ⅱ) 단계를 반복하는 단계를 더 포함하는 것인 관찰 방법.
- 제1항에 있어서, 신장 질환의 치료를 시작하거나 끝낸 후에 ⅰ) 및 ⅱ) 단계를 반복하는 단계를 더 포함하는 것인 관찰 방법.
- 제1항에 있어서, 상기 신장 질환은 허혈 후 신장 손상인 것인 방법.
- 제1항에 있어서, 상기 신장 질환은 급성 신부전증, 급성 세뇨관 괴사 또는 급성 세뇨관 간질성 신증을 일으킬 수 있는 질환인 것인 방법.
- 제1항에 있어서, 상기 신장 질환은 신독성제에 의한 것인 방법.
- 제1항에 있어서, 상기 i)에서 측정한 NGAL의 농도를 제2 컷오프 값과 비교하는 단계를 더 포함하고, 상기 제2 컷오프 값은 투석에 의한 환자의 치료를 필요로 하는 신장 질환 정도와 관련이 없는 낮은 NGAL 농도를 배제하도록 선택된 값으로서 1000 ng/㎖ ~ 3000 ng/㎖ 범위인 방법.
- 삭제
- 제1항에 있어서, NGAL은 NGAL에 특이적으로 결합하는 분자에 의하여 측정되는 것인 방법.
- 제1항에 있어서, 상기 체액은 소변인 것인 방법.
- 제1항에 있어서, 상기 체액은 혈액 또는 혈장 또는 혈청인 것인 방법.
- ⅰ) 인간의 체액 시료 중 인간 호중구 젤라티나제 결합 리포칼린 (NGAL)의 농도를 측정하는 단계와,ⅱ) 소정의 시간 후에 동일인으로부터 채취한 추가 체액 시료로 단계 ⅰ)을 반복하는 단계와,ⅲ) 단계 ⅱ)에서 결정된 NGAL 농도가 단계 i)에서 결정된 NGAL 농도에 비하여 50 ng/㎖ 이상 높은 지의 여부를 표시하는 단계를 포함하는,인간의 신장 질환 발병을 관찰하기 위한 정보를 제공하는 방법.
- 제18항에 있어서, 단계 iii)은 단계 ⅱ)에서 결정된 NGAL 농도가 단계 i)에서 결정된 NGAL 농도에 비하여 100 ng/㎖ 이상 높은 지의 여부를 표시하는 것인 방법.
- 제18항에 있어서, ⅱ)와 ⅲ) 단계를 반복하는 단계를 더 포함하는 것인 방법.
- 제18항에 있어서, 상기 소정의 시간은 24 시간 이하인 것인 방법.
- 삭제
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63750304P | 2004-12-20 | 2004-12-20 | |
US60/637,503 | 2004-12-20 | ||
US71930705P | 2005-09-21 | 2005-09-21 | |
US60/719,307 | 2005-09-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
KR20070108158A KR20070108158A (ko) | 2007-11-08 |
KR100971305B1 true KR100971305B1 (ko) | 2010-07-20 |
KR100971305B9 KR100971305B9 (ko) | 2022-07-11 |
Family
ID=36011033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077016768A KR100971305B1 (ko) | 2004-12-20 | 2005-12-20 | 신장 질환용 진단 표지로서의 호중구 젤라티나제 결합리포칼린 (ngal)의 측정 |
Country Status (18)
Country | Link |
---|---|
US (3) | US20090170143A1 (ko) |
EP (4) | EP3489689B1 (ko) |
JP (1) | JP4741603B2 (ko) |
KR (1) | KR100971305B1 (ko) |
CN (1) | CN101163971B (ko) |
AT (1) | ATE448484T1 (ko) |
AU (1) | AU2005318689B2 (ko) |
CA (1) | CA2591113C (ko) |
DE (1) | DE602005013288D1 (ko) |
DK (3) | DK3489689T3 (ko) |
ES (4) | ES2703434T3 (ko) |
HK (1) | HK1105454A1 (ko) |
IL (1) | IL183872A (ko) |
NZ (1) | NZ555926A (ko) |
PL (2) | PL1831699T3 (ko) |
SI (1) | SI1831699T1 (ko) |
WO (1) | WO2006066587A1 (ko) |
ZA (1) | ZA200705776B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210100833A (ko) * | 2020-02-07 | 2021-08-18 | 고려대학교 산학협력단 | 혈액 종양 질환 특이적 바이오마커 |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE437371T1 (de) * | 2003-03-27 | 2009-08-15 | Childrens Hosp Medical Center | Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung |
US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
US20080090304A1 (en) * | 2006-10-13 | 2008-04-17 | Barasch Jonathan Matthew | Diagnosis and monitoring of chronic renal disease using ngal |
US20090197280A1 (en) | 2006-05-30 | 2009-08-06 | Kristian Bangert | Methods and Devices for Rapid Assessment of Severity of Injury |
EP2064553B2 (en) * | 2006-08-07 | 2023-06-07 | Antibodyshop A/S | Diagnostic test to exclude significant renal injury |
WO2008060607A2 (en) * | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
EP2095106B1 (en) * | 2006-11-14 | 2013-03-20 | Alere San Diego, Inc. | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
US8101366B2 (en) * | 2006-12-20 | 2012-01-24 | Antibodyshop A/S | Assessment of patients with sepsis to determine a requirement for therapeutic intervention with an anti-inflammatory and/or anticoagulatory agent |
EP2126562B1 (en) * | 2007-02-23 | 2014-12-31 | Physicians Choice Laboratory Services, LLC | Clinical intervention directed diagnostic methods |
CN101680903A (zh) * | 2007-03-21 | 2010-03-24 | 比奥波托诊断股份公司 | 肾损伤的诊断试验 |
US20090123946A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
WO2009059259A2 (en) * | 2007-10-31 | 2009-05-07 | Children's Hospital Medical Center | Detection of worsening renal disease in subjects with systemic lupus erythematosus |
ES2475990T5 (es) * | 2007-11-15 | 2017-07-06 | Bioporto Diagnostics A/S | Uso diagnóstico de formas moleculares individuales de un biomarcador |
EP2257813A4 (en) * | 2008-03-12 | 2011-11-02 | Univ Columbia | NGAL WITH HIGH MOLECULAR WEIGHT AS BIOMARKER FOR CHRONIC KIDNEY DISEASE |
US7977110B2 (en) | 2008-06-02 | 2011-07-12 | Children's Hospital Medical Center | Method for distinguishing between kidney dysfunctions |
EP2324355B1 (en) | 2008-08-28 | 2014-01-22 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US20100105150A1 (en) * | 2008-10-24 | 2010-04-29 | Abbott Laboratories | Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal |
WO2010054025A1 (en) | 2008-11-05 | 2010-05-14 | Abbott Laboratories | Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use |
WO2010058378A1 (en) | 2008-11-21 | 2010-05-27 | Phadia Ab | Methods, devices and kits for detecting or monitoring acute kidney injury |
US20100233740A1 (en) * | 2009-02-12 | 2010-09-16 | Jonathan Barasch | Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis |
US20100233739A1 (en) * | 2009-02-12 | 2010-09-16 | Jonathan Barasch | Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction |
ES2350078B1 (es) * | 2009-05-19 | 2011-11-15 | Consejo Superior De Investigaciones Científicas (Csic) | Celula del smf modificada geneticamente para sobreexpresar ngal y su uso como medicamento |
US20120214177A1 (en) * | 2009-06-17 | 2012-08-23 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for diagnosis of urosepsis and urinary tract infection |
WO2011017682A1 (en) * | 2009-08-07 | 2011-02-10 | Rules-Based Medicine, Inc. | Devices for detecting renal disorders |
US20120315649A1 (en) * | 2009-08-28 | 2012-12-13 | Astute Medical ,Inc. a corporation | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
WO2011053832A1 (en) * | 2009-10-29 | 2011-05-05 | The Trustees Of Columbia University In The City Of New York | Use of urinary ngal to diagnose sepsis in very low birth weight infants |
US20110195903A1 (en) * | 2009-12-15 | 2011-08-11 | Adra Chaker N | Methods and compositions for detecting recessive familial fsgs and uses thereof |
CN102072960A (zh) * | 2010-03-29 | 2011-05-25 | 武汉生之源生物科技有限公司 | 一种样本中中性粒细胞明胶酶相关脂质运载蛋白的检测方法 |
WO2011149962A1 (en) | 2010-05-24 | 2011-12-01 | The Trustees Of Columbia University In The City Of New York | Mutant ngal proteins and uses thereof |
IN2013MN00441A (ko) * | 2010-10-07 | 2015-05-29 | Astute Medical Inc | |
CN102253217B (zh) * | 2011-04-07 | 2013-08-07 | 武汉生之源生物科技有限公司 | 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
TW201250248A (en) * | 2011-04-25 | 2012-12-16 | Kyowa Medex Co Ltd | Prognostication method of renal failure |
NL2007112C2 (en) | 2011-07-14 | 2013-01-15 | Brainlabs B V | Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness. |
US20130062516A1 (en) * | 2011-09-09 | 2013-03-14 | Hsien-Shou Kuo | Diganosis of a renal disease by oxygen and hydrogen isotopes in a biological sample |
GB2519208A (en) * | 2012-01-11 | 2015-04-15 | Craig Venter Inst J | Metaproteomic method for diagnosis of bacteriuria, urogenital tract and kidney infections from urinary pellet samples |
CN102662064A (zh) * | 2012-04-26 | 2012-09-12 | 苏州照康生物技术有限公司 | 检测中性粒细胞明胶酶相关脂质运载蛋白的免疫比浊试剂盒及其制备方法 |
WO2014081980A2 (en) | 2012-11-21 | 2014-05-30 | The Trustees Of Columbia University In The City Of New York | Mutant ngal proteins and uses thereof |
CN203441604U (zh) | 2013-02-15 | 2014-02-19 | 通用电气公司 | 用于降低燃气涡轮系统中的背压的系统 |
US9651547B2 (en) | 2013-03-14 | 2017-05-16 | Abbott Point Of Care Inc. | Electrochemical methods and devices for amending urine samples for immunosensor detection |
US9488663B2 (en) | 2013-03-14 | 2016-11-08 | Abbott Point Of Care Inc. | Electrochemical methods and devices for amending urine samples for immunosensor detection |
RS62633B1 (sr) | 2013-03-15 | 2021-12-31 | Protagonist Therapeutics Inc | Analozi hepcidina i njihove primene |
KR101590622B1 (ko) | 2013-10-24 | 2016-02-01 | (주)메디컬그룹베스티안 | 화상 중증도 판단 방법 |
JP6585162B2 (ja) | 2014-05-16 | 2019-10-02 | プロタゴニスト セラピューティクス, インコーポレイテッド | α4β7インテグリンチオエーテルペプチドアンタゴニスト |
RU2736637C9 (ru) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника |
WO2016079219A1 (en) * | 2014-11-19 | 2016-05-26 | Koninklijke Philips N.V. | Diagnostic method employing hnl |
CN104502596A (zh) * | 2014-12-23 | 2015-04-08 | 温州医科大学 | 一种慢性肾病诊断试剂盒 |
KR101657881B1 (ko) * | 2015-03-16 | 2016-09-19 | 대구한의대학교산학협력단 | 타깃 바이오마커에 고특이적이며 고선택적 결합이 가능한 펩타이드 프로브 및 그를 이용한 급성 및 만성 신장질환 조기진단용 바이오칩 |
WO2017027858A1 (en) | 2015-08-12 | 2017-02-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating volume depletion and kidney injury |
EP3184116B1 (en) | 2015-12-23 | 2020-09-16 | National Taiwan Normal University | Neutrophil gelatinase-associated lipocalin for use in prevention or treatment of polycystic kidney disease |
TWI581802B (zh) | 2015-12-23 | 2017-05-11 | 國立臺灣師範大學 | 嗜中性白血球膠原蛋白質酶相關疏水性蛋白質之製藥用途 |
WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
US20200064357A1 (en) * | 2016-11-09 | 2020-02-27 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
KR102094608B1 (ko) * | 2018-08-08 | 2020-04-23 | 고려대학교 산학협력단 | 혈액암의 분류 및 예후 판단에 필요한 정보를 제공하는 방법 |
CN109781990A (zh) * | 2018-12-25 | 2019-05-21 | 无锡市人民医院 | 一种β-痕迹蛋白检测试剂盒及制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004088276A2 (en) * | 2003-03-27 | 2004-10-14 | Children's Hospital Medical Center | A method and kit for detecting the early onset of renal tubular cell injury |
WO2005121788A2 (en) * | 2004-06-07 | 2005-12-22 | Children's Hospital Medical Center | Method for the early detection of renal disease and injury |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3635091A (en) * | 1970-08-31 | 1972-01-18 | Frederick D Linzer | Midstream urine specimen and fractional fluid collectors |
IT1074038B (it) * | 1976-08-05 | 1985-04-17 | Simes | Esteri della epinina |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4357343A (en) * | 1981-06-26 | 1982-11-02 | Baxter Travenol Laboratories, Inc. | Nutritional composition for management of renal failure |
US4659678A (en) * | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
US4640909A (en) * | 1985-05-07 | 1987-02-03 | J. T. Baker Chemical Company | Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction |
US5939272A (en) * | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
US5200319A (en) * | 1989-10-27 | 1993-04-06 | The General Hospital Corporation | Diagnosis of glomerulonephritis |
JP2912413B2 (ja) * | 1990-03-28 | 1999-06-28 | 東亜医用電子株式会社 | 粒度分布作成方法 |
US5405832A (en) * | 1991-11-27 | 1995-04-11 | Immtech International Inc. | Method of treating non-streptococcal bacterial infections |
US5273961A (en) * | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
SE9401351D0 (sv) | 1994-04-21 | 1994-04-21 | Venge | A method for diagnosis |
US5552313A (en) * | 1994-11-21 | 1996-09-03 | Kansas University | DNA encoding mouse phosphotriesterase-related protein |
US5750345A (en) * | 1995-10-31 | 1998-05-12 | Evanston Hospital Corporation | Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders |
US5627034A (en) * | 1995-12-05 | 1997-05-06 | Wisconsin Alumni Research Foundation | Assay for carcinoma proliferative status by measuring NGAL expression level |
TR199802421T2 (xx) * | 1996-05-24 | 1999-02-22 | Biogen , Inc. | Doku yenilenmesini d�zenleyen maddeler. |
AU8899298A (en) * | 1997-08-06 | 1999-03-01 | Zymogenetics Inc. | Lipocalin homologs |
US6309888B1 (en) * | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
AUPP784398A0 (en) * | 1998-12-21 | 1999-01-21 | Monash University | Kidney disease detection and treatment |
WO2000078919A1 (en) * | 1999-06-18 | 2000-12-28 | Michigan State University | Method and apparatus for the detection of volatile products in a sample |
US6762032B1 (en) * | 1999-08-23 | 2004-07-13 | Biocrystal, Ltd. | Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response |
JP2004510981A (ja) * | 2000-10-03 | 2004-04-08 | ロウェット、リサーチ、インスティテュート | ピロール含有生体化合物の測定方法およびピロール含有生体化合物 |
US6564385B2 (en) * | 2000-10-06 | 2003-05-20 | Mccarthy Daniel J. | Handling device |
MXPA03003281A (es) * | 2000-10-13 | 2004-05-21 | Childrens Medical Center | Deteccion enzimatica no invasiva de estados asociados con la remodelacion de tejidos. |
FI20010019A (fi) * | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen diagnostisoimiseksi |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20040203083A1 (en) * | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
DE10120614A1 (de) | 2001-04-26 | 2002-10-31 | Sms Demag Ag | Kühlplatte |
ATE439588T1 (de) * | 2001-05-04 | 2009-08-15 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
US20030119209A1 (en) * | 2001-12-21 | 2003-06-26 | Kaylor Rosann Marie | Diagnostic methods and devices |
US6986995B2 (en) * | 2002-02-28 | 2006-01-17 | Prometheus Laboratories, Inc. | Methods of diagnosing liver fibrosis |
US6847451B2 (en) * | 2002-05-01 | 2005-01-25 | Lifescan, Inc. | Apparatuses and methods for analyte concentration determination |
GB0215509D0 (en) * | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
US7056702B2 (en) * | 2002-12-16 | 2006-06-06 | Kimberly Clark Co | Detecting lipocalin |
US7776824B2 (en) * | 2004-05-06 | 2010-08-17 | The Trustees Of Columbia University | NGAL for reduction and amelioration of ischemic and nephrotoxic injuries |
US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
US20080090304A1 (en) * | 2006-10-13 | 2008-04-17 | Barasch Jonathan Matthew | Diagnosis and monitoring of chronic renal disease using ngal |
AU2007217861A1 (en) * | 2006-02-17 | 2007-08-30 | Children's Medical Center Corporation | Free NGAL as a biomarker for cancer |
US20080061149A1 (en) * | 2006-09-11 | 2008-03-13 | Colin Tanner | Proximity payment card with security interlock |
US20090123970A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
US20090124022A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
DE102008025144A1 (de) * | 2008-05-26 | 2009-12-03 | Siemens Aktiengesellschaft | Anordnung zur Erhöhung der Lese- und Schreibsicherheit von RFID-Labeln |
-
2005
- 2005-12-20 ES ES17152153T patent/ES2703434T3/es active Active
- 2005-12-20 SI SI200530897T patent/SI1831699T1/sl unknown
- 2005-12-20 AT AT05820913T patent/ATE448484T1/de active
- 2005-12-20 AU AU2005318689A patent/AU2005318689B2/en active Active
- 2005-12-20 PL PL05820913T patent/PL1831699T3/pl unknown
- 2005-12-20 ES ES18195687T patent/ES2818028T3/es active Active
- 2005-12-20 DK DK18195687.1T patent/DK3489689T3/da active
- 2005-12-20 US US11/722,025 patent/US20090170143A1/en not_active Abandoned
- 2005-12-20 EP EP18195687.1A patent/EP3489689B1/en active Active
- 2005-12-20 WO PCT/DK2005/000806 patent/WO2006066587A1/en active Application Filing
- 2005-12-20 CN CN2005800481759A patent/CN101163971B/zh active Active
- 2005-12-20 ES ES05820913T patent/ES2336345T3/es active Active
- 2005-12-20 EP EP09154624.2A patent/EP2128625B1/en active Active
- 2005-12-20 EP EP17152153.7A patent/EP3208616B1/en active Active
- 2005-12-20 CA CA2591113A patent/CA2591113C/en active Active
- 2005-12-20 KR KR1020077016768A patent/KR100971305B1/ko active IP Right Review Request
- 2005-12-20 JP JP2007547181A patent/JP4741603B2/ja active Active
- 2005-12-20 PL PL18195687T patent/PL3489689T3/pl unknown
- 2005-12-20 ES ES09154624.2T patent/ES2622467T3/es active Active
- 2005-12-20 EP EP05820913A patent/EP1831699B1/en not_active Revoked
- 2005-12-20 NZ NZ555926A patent/NZ555926A/en not_active IP Right Cessation
- 2005-12-20 DE DE602005013288T patent/DE602005013288D1/de active Active
- 2005-12-20 DK DK09154624.2T patent/DK2128625T3/en active
- 2005-12-20 DK DK05820913.1T patent/DK1831699T3/da active
-
2007
- 2007-06-12 IL IL183872A patent/IL183872A/en not_active IP Right Cessation
- 2007-07-13 ZA ZA2007/05776A patent/ZA200705776B/en unknown
- 2007-12-18 HK HK07113788.2A patent/HK1105454A1/xx unknown
-
2015
- 2015-01-08 US US14/592,016 patent/US20150132772A1/en not_active Abandoned
- 2015-09-16 US US14/855,587 patent/US20160003851A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004088276A2 (en) * | 2003-03-27 | 2004-10-14 | Children's Hospital Medical Center | A method and kit for detecting the early onset of renal tubular cell injury |
WO2005121788A2 (en) * | 2004-06-07 | 2005-12-22 | Children's Hospital Medical Center | Method for the early detection of renal disease and injury |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210100833A (ko) * | 2020-02-07 | 2021-08-18 | 고려대학교 산학협력단 | 혈액 종양 질환 특이적 바이오마커 |
KR102293024B1 (ko) | 2020-02-07 | 2021-08-24 | 고려대학교 산학협력단 | 혈액 종양 질환 특이적 바이오마커 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100971305B1 (ko) | 신장 질환용 진단 표지로서의 호중구 젤라티나제 결합리포칼린 (ngal)의 측정 | |
EP2160478B1 (en) | Predictive diagnostics for kidney disease | |
US7141382B1 (en) | Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality | |
US20190170770A1 (en) | Diagnostic Test to Exclude Significant Renal Injury | |
EP2137538B1 (en) | Diagnostic test for renal injury | |
Class et al. | Patent application title: DIAGNOSTIC TEST TO EXCLUDE SIGNIFICANT RENAL INJURY Inventors: Lars Otto Uttenthal (Salamanca, ES) Antibodyshop A/s (Gentofte, DE) Kristian Bangert (Holte, DE) Assignees: AntibodyShop A/S |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130709 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140711 Year of fee payment: 5 |
|
J204 | Request for invalidation trial [patent] | ||
FPAY | Annual fee payment |
Payment date: 20160705 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170628 Year of fee payment: 8 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2016100000422; TRIAL DECISION FOR INVALIDATION REQUESTED 20160219 Effective date: 20180131 |
|
FPAY | Annual fee payment |
Payment date: 20180705 Year of fee payment: 9 |
|
J202 | Request for trial for correction [limitation] | ||
J202 | Request for trial for correction [limitation] | ||
FPAY | Annual fee payment |
Payment date: 20190703 Year of fee payment: 10 |
|
J121 | Written withdrawal of request for trial | ||
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2018200003260; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20180406 Effective date: 20190315 |
|
J303 | Written judgement (supreme court) |
Free format text: TRIAL NUMBER: 2019300010456; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20190403 Effective date: 20220616 |